Common symptoms in advanced cancer

Surgical Clinics of North America

Volumn 85, Issue 2, 2005, Pages 237-255

  Lagman, Ruth L ^a   Davis, Mellar P ^a   LeGrand, Susan B ^a   Walsh, Declan ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANABOLIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BRONCHODILATING AGENT; BUTYROPHENONE; BUTYROPHENONE DERIVATIVE; CANNABINOID; CHLORPROMAZINE; CORTICOSTEROID; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; ICOSAPENTAENOIC ACID; MIDAZOLAM; MORPHINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OPIATE; OXYGEN; PHENOBARBITAL; PHENOTHIAZINE DERIVATIVE; PROGESTERONE; SEROTONIN ANTAGONIST; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

ADVANCED CANCER; ANOREXIA; ANXIETY; BRAIN METASTASIS; CACHEXIA; CANCER RESEARCH; CATABOLISM; CLINICAL TRIAL; CONSTIPATION; DELIRIUM; DIETARY INTAKE; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; DYSPHORIA; DYSPNEA; EMOTIONAL STRESS; EPISTAXIS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; HUMAN; INSULIN RESISTANCE; INTESTINE OBSTRUCTION; LEAN BODY WEIGHT; METABOLIC DISORDER; MOOD DISORDER; MOTION SICKNESS; NAUSEA; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

EID: 17044378117     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2004.11.004     Document Type: Review

References (118)

1. A. Inui Cancer anorexia-cachexia syndrome: current issues in research and management CA Cancer J Clin 52 2 2002 72 91
2. E. Bruera ABC of palliative care. Anorexia, cachexia, and nutrition BMJ 315 7117 1997 1219 1222
3. A. Molassiotis Anorexia and weight loss in long-term survivors of haematological malignancies J Clin Nurs 12 6 2003 925 927
4. R.M. Goldberg, and C.L. Loprinzi Cancer anorexia/cachexia Cancer Treat Res 100 1999 31 41
5. M.P. Davis, R. Dreicer, and D. Walsh Appetite and cancer-associated anorexia: a review J Clin Oncol 22 8 2004 1510 1517
6. M.J. Tisdale Cancer anorexia and cachexia Nutrition 17 5 2001 438 442
7. I. Bosaeus, P. Daneryd, and E. Svanberg Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients Int J Cancer 93 3 2001 380 383
8. G. Costa, and A.P. Weathers Cancer and the nutrition of the host J Am Diet Assoc 44 1964 15 17
9. M.J. Tisdale Metabolic abnormalities in cachexia and anorexia Nutrition 16 10 2000 1013 1014
10. E. Holm, E. Hagmuller, and U. Staedt Substrate balances across colonic carcinomas in humans Cancer Res 55 6 1995 1373 1378
11. C.P. Holroyde, T.G. Gabuzda, and R.C. Putnam Altered glucose metabolism in metastatic carcinoma Cancer Res 35 12 1975 3710 3714
12. K. Lundholm, S. Edstrom, and L. Ekman Metabolism in peripheral tissues in cancer patients Cancer Treat Rep 65 Suppl 5 1981 79 83
13. E. Gibney, M. Elia, and S.A. Jebb Total energy expenditure in patients with small-cell lung cancer: results of a validated study using the bicarbonate-urea method Metabolism 46 12 1997 1412 1417
14. I. Warnold, K. Lundholm, and T. Schersten Energy balance and body composition in cancer patients Cancer Res 38 6 1978 1801 1807
15. L. Lindmark, K. Bennegard, and E. Eden Resting energy expenditure in malnourished patients with and without cancer Gastroenterology 87 2 1984 402 408
16. A. Hyltander, U. Korner, and K.G. Lundholm Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours Eur J Clin Invest 23 1 1993 46 52
17. J.M. Argiles, R. Moore-Carrasco, and G. Fuster Cancer cachexia: the molecular mechanisms Int J Biochem Cell Biol 35 4 2003 405 409
18. J.M. Argiles, S. Busquets, and F.J. Lopez-Soriano The role of uncoupling proteins in pathophysiological states Biochem Biophys Res Commun 293 4 2002 1145 1152
19. P.M. Sanders, and M.J. Tisdale Effect of zinc-alpha(2)-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue Cancer Lett 212 1 2004 71 81
20. C. Gercel-Taylor, D.L. Doering, and F.B. Kraemer Aberrations in normal systemic lipid metabolism in ovarian cancer patients Gynecol Oncol 60 1 1996 35 41
21. A.M. Rofe, C.S. Bourgeois, and P. Coyle Altered insulin response to glucose in weight-losing cancer patients Anticancer Res 14 2B 1994 647 650
22. D. Heber, L.O. Byerley, and N.S. Tchekmedyian Hormonal and metabolic abnormalities in the malnourished cancer patient: effects on host-tumor interaction JPEN J Parenter Enteral Nutr 16 Suppl 6 1992 60S 64S
23. P. Groundwater, S.A. Beck, and C. Barton Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients Br J Cancer 62 5 1990 816 821
24. M. Jeevanandam, G.D. Horowitz, and S.F. Lowry Cancer cachexia and the rate of whole body lipolysis in man Metabolism 35 4 1986 304 310
25. S. Klein, and R.R. Wolfe Whole-body lipolysis and triglyceride-fatty acid cycling in cachectic patients with esophageal cancer J Clin Invest 86 5 1990 1403 1408
26. S. Khan, and M.J. Tisdale Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor Int J Cancer 80 3 1999 444 447
27. M.K. Marshall, W. Doerrler, and K.R. Feingold Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes Endocrinology 135 1 1994 141 147
28. O. Ishiko, T. Yasui, and K. Hirai Lipolytic activity of anemia-inducing substance from tumor-bearing rabbits Nutr Cancer 33 2 1999 201 205
29. O. Ishiko, T. Sumi, and H. Yoshida Anemia-inducing substance is related to elimination of lipolytic hyperactivity by cyclic plasma perfusion in human cancer cachexia Nutr Cancer 37 2 2000 169 172
30. C. Grunfeld, and K.R. Feingold Regulation of lipid metabolism by cytokines during host defense Nutrition 12 Suppl 1 1996 S24 S26
31. C. Bing, Y. Bao, and J. Jenkins Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia Proc Natl Acad Sci USA 101 8 2004 2500 2505
32. S.T. Russell, T.P. Zimmerman, and B.A. Domin Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein Biochim Biophys Acta 1636 1 2004 59 68
33. D. Attaix, L. Combaret, and T. Tilignac Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia Mol Biol Rep 26 1-2 1999 77 82
34. P.-O. Hasselgren, C. Wray, and J. Mammen Breakthroughs and views Biochem Biophys Res Commun 290 2002 1 10
35. A. Giordano, M. Calvani, and O. Petillo Skeletal muscle metabolism in physiology and in cancer disease J Cell Biochem 90 1 2003 170 186
36. N. Sarhill, F. Mahmoud, and D. Walsh Evaluation of nutritional status in advanced metastatic cancer Support Care Cancer 11 10 2003 652 659
37. J.M. Ribaudo, D. Cella, and E.A. Hahn Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire Qual Life Res 9 10 2000 1137 1146
38. L. Thoresen, I. Fjeldstad, and K. Krogstad Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool Palliat Med 16 1 2002 33 42
39. D.F. Cella, J. VonRoenn, and S. Lloyd The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia/cachexia Qual Life Res 4 3 1995 221 231
40. M.R. Smith, V. Fuchs, and E.J. Anderson Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer Nutrition 18 7-8 2002 574 577
41. S. Toso, A. Piccoli, and M. Gusella Altered tissue electric properties in lung cancer patients as detected by bioelectric impedance vector analysis Nutrition 16 2 2000 120 124
42. E.W. Fredrix, W.H. Saris, and P.B. Soeters Estimation of body composition by bioelectrical impedance in cancer patients Eur J Clin Nutr 44 10 1990 749 752
43. F. Bozzetti, C. Gavazzi, and P. Ferrari Effect of total parenteral nutrition on the protein kinetics of patients with cancer cachexia Tumori 86 5 2000 408 411
44. D.O. McCarthy Rethinking nutritional support for persons with cancer cachexia Biol Res Nurs 5 1 2003 3 17
45. M.P. Davis New drugs for the anorexia-cachexia syndrome Curr Oncol Rep 4 3 2002 264 274
46. J.M. Argiles, S.H. Meijsing, and J. Pallares-Trujillo Cancer cachexia: a therapeutic approach Med Res Rev 21 1 2001 83 101
47. F. De Conno, C. Martini, and E. Zecca Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial Eur J Cancer 34 11 1998 1705 1709
48. A. Jatoi, H.E. Windschitl, and C.L. Loprinzi Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study J Clin Oncol 20 2 2002 567 573
49. C.L. Loprinzi, D.J. Schaid, and A.M. Dose Body-composition changes in patients who gain weight while receiving megestrol acetate J Clin Oncol 11 1 1993 152 154
50. M.D. Barber, J.A. Ross, and K.C. Fearon Disordered metabolic response with cancer and its management World J Surg 24 6 2000 681 689
51. J.M. Argiles, R. Moore-Carrasco, and S. Busquets Catabolic mediators as targets for cancer cachexia Drug Discov Today 8 18 2003 838 844
52. C.P. Burns, S. Halabi, and G.H. Clamon Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473 Clin Cancer Res 5 12 1999 3942 3947
53. M.D. Barber, D.C. McMillan, and T. Preston Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement Clin Sci (Lond) 98 4 2000 389 399
54. S.J. Wigmore, M.D. Barber, and J.A. Ross Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer Nutr Cancer 36 2 2000 177 184
55. R.L. Fainsinger, A. Waller, and M. Bercovici A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients Palliat Med 14 4 2000 257 265
56. E. Bruera, B. Schmitz, and J. Pither The frequency and correlates of dyspnea in patients with advanced cancer J Pain Symptom Manage 19 5 2000 357 362
57. D.J. Dudgeon, and M. Lertzman Dyspnea in the advanced cancer patient J Pain Symptom Manage 16 4 1998 212 219
58. D.J. Dudgeon, M. Lertzman, and G.R. Askew Physiological changes and clinical correlations of dyspnea in cancer outpatients J Pain Symptom Manage 21 5 2001 373 379
59. A.G. Gift Validation of a vertical visual analogue scale as a measure of clinical dyspnea Rehabil Nurs 14 6 1989 323 325
60. A.G. Gift, and G. Narsavage Validity of the numeric rating scale as a measure of dyspnea Am J Respir Crit Care Med 7 1998 200 204
61. A.L. Jennings, A.N. Davies, and J.P. Higgins Opioids for the palliation of breathlessness in terminal illness Cochrane Database of Systematic Reviews 4 2001 CD002066
62. E. Bruera, R. Sala, and O. Spruyt Nebulized versus subcutaneous morphine for the treatment of cancer dyspnea: a randomized, controlled trial Support Care Cancer 12 6 2004 405
63. J. Congleton, and M.F. Muers The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy Respir Med 89 4 1995 291 296
64. D.J. Dudgeon, L. Kristjanson, and J.A. Sloan Dyspnea in cancer patients: prevalence and associated factors J Pain Symptom Manage 21 2 2001 95 102
65. A.H. Navigante, M.A. Castro, and L.C. Cerchietti Oral morphine versus oral midazolam on dyspnea perception management. A prospective randomized study in ambulatory patients with cancer Support Care Cancer 12 6 2004 420
66. P.A. Neill, P.B. Morton, and R.D. Stark Chlorpromazine - a specific effect on breathlessness? Br J Clin Pharmac 19 1985 793 797
67. S. Booth, M.J. Kelly, and N.P. Cox Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med 153 5 1996 1515 1518
68. P.G. Lawlor, B. Gagnon, and I.L. Mancini Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study Arch Intern Med 160 6 2000 786 794
69. W. Breitbart, C. Gibson, and A. Tremblay The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses Psychosomatics 43 3 2002 183 194
70. D.J. Casarett, and S.K. Inouye Diagnosis and management of delirium near the end of life Ann Intern Med 135 1 2001 32 40
71. P.T. Trzepacz Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine Semin Clin Neuropsychiatry 5 2 2000 132 148
72. M.H. Johnson Assessing confused patients J Neurol Neurosurg Psychiatry 71 Suppl 1 2001 i7 i12
73. P.G. Lawlor Delirium and dehydration: some fluid for thought? Support Care Cancer 10 6 2002 445 454
74. W. Breitbart, A. Tremblay, and C. Gibson An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients Psychosomatics 43 3 2002 175 182
75. D.J. Meagher Delirium: optimising management BMJ 322 7279 2001 144 149
76. T.L. Schwartz, and P.S. Masand The role of atypical antipsychotics in the treatment of delirium Psychosomatics 43 3 2002 171 174
77. W. Breitbart, R. Marotta, and M.M. Platt A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients Am J Psychiatry 153 2 1996 231 237
78. J.D. Cowan, and D. Walsh Terminal sedation in palliative medicine - definition and review of the literature Support Care Cancer 9 6 2001 403 407
79. R. Fainsinger, M.J. Miller, and E. Bruera Symptom control during the last week of life on a palliative care unit J Palliat Care 7 1 1991 5 11
80. E.B. Curtis, R. Krech, and T.D. Walsh Common symptoms in patients with advanced cancer J Palliat Care 7 2 1991 25 29
81. S. Grond, D. Zech, and C. Diefenbach Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic J Pain Symptom Manage 9 6 1994 372 382
82. V.A. Rhodes, and R.W. McDaniel Nausea, vomiting, and retching: complex problems in palliative care CA Cancer J Clin 51 4 2001 232 248 [quiz 249-52]
83. M.P. Davis, and D. Walsh Treatment of nausea and vomiting in advanced cancer Support Care Cancer 8 6 2000 444 452
84. E. Bruera, and C. Sweeney Chronic nausea and vomiting G.M. Berger R.K. Portenoy D.E. Weissman Principles and practice of palliative care and supportive oncology 2002 Lippincott Williams & Wilkins Philadelphia 57 60
85. S. Kinghorn Palliative care. Nausea and vomiting Nurs Times 93 33 1997 57 60
86. Twycross R, Back I. Nausea and vomiting in advanced cancer. Eur J Palliat Care 1998;5:39-45.
87. N. Bhana, R.H. Foster, and R. Olney Olanzapine: an updated review of its use in the management of schizophrenia Drugs 61 1 2001 111 161
88. K.A. Nelson, and D. Walsh The use of cannabinoids in palliative medicine Prog Palliative Care 6 1998 160 163
89. D.R. Gandara, W.H. Harvey, and G.G. Monaghan The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo Semin Oncol 19 4Suppl 10 1992 67 71
90. Poli-Begelli S, Rodriguez-Pereira J, Carioes AD, et al for the Aprepitant Protocol 054 Study Group. Addition of the neurokinin/receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer Lett 2003;97:3090-8.
91. M.A. Brooksbank, P.A. Game, and M.A. Ashby Palliative venting gastrostomy in malignant intestinal obstruction Palliat Med 16 6 2002 520 526
92. Oishi H, Shindo H, Shirotani N, et al. The experience of improved quality of life at home for the long term, using percutaneous trans-esophageal gastro-tubing drainage for a cases with terminal stage cancer. J Tokyo Wom Med Univ 2001;71(3):188-92.
93. D. Cella, K. Davis, and W. Breitbart Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors J Clin Oncol 19 14 2001 3385 3391
94. V. Mock, B. Piper, and P. Sabbatini National comprehensive network fatigue practice guidelines Oncology 14 11A 2000 151 161
95. C.A. Miaskowski, and R.K. Portenoy Fatigue A.M. Berger R.K. Portenoy D.E. Weissman Principles and practice of palliative care and supportive oncology 2002 Lippincott Williams & Wilkins Philadelphia 141 153
96. H. Nevenschwander, and E. Bruera Asthenia-cachexia E. Bruera I. Higginson Cachexia-anorexia in cancer patients 1996 Oxford University Press New York 57 75
97. L.B. Krupp, N.G. LaRocca, and J. Muir-Nash The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus Arch Neurol 46 10 1989 1121 1123
98. D. Rhoten Fatigue and the post-surgical patient Concept clarification in nursing 1996 ASPED Rockville (MD) 277 300
99. E.A. Barnes, and E. Bruera Fatigue in patients with advanced cancer: a review Int J Gynecol Cancer 12 5 2002 424 428
100. T.R. Mendoza, X.S. Wang, and C.S. Cleeland The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory Cancer 85 5 1999 1186 1196
101. B. Piper, A. Lindsey, and M. Dodd The development of an instrument to measure the subjective dimension of fatigue S. Funk E. Tornquist M. Champagne Key aspects of comfort management of pain fatigue and nausea 1989 Springer New York 199 208
102. T. Chalder, G. Berelowitz, and T. Pawlikowska Development of a fatigue scale J Psychosom Res 37 2 1993 147 153
103. T. Kaasa, J. Loomis, and K. Gillis The Edmonton Functional Assessment Tool: preliminary development and evaluation for use in palliative care J Pain Symptom Manage 13 1 1997 10 19
104. D.A. Karnofsky, and J.H. Burchenal The clinical evaluation of chemotherapeutic agents in cancer C.M. Macleod Evaluation of chemotherapeutic agents 1949 Columbia University Press New York 191 205
105. V. Mock Fatigue management: evidence and guidelines for practice Cancer 92 Suppl 6 2001 1699 1707
106. F.C. Dimeo Effects of exercise on cancer-related fatigue Cancer 92 Suppl 6 2001 1689 1693
107. N. Sarhill, D. Walsh, and K.A. Nelson Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study Am J Hosp Palliat Care 18 3 2001 187 192
108. K.W. Rammwhan, J.H. Rosenberg, and D.J. Lynn Efficacy and safety of modafinil (provigil) for the treatment of fatigue in multiple sclerosis: a two center phase 2 study J Neurol Neurosurg Psychiatry 72 2002 179 183
109. E. Bruera, E. Roca, and L. Cedaro Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study Cancer Treat Rep 69 7-8 1985 751 754
110. E. Bruera, S. Ernst, and N. Hagen Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study Cancer Prev Control 2 2 1998 74 78
111. M. Levy Management of opioid-induced bowel dysfunction J Nat Comp Cancer Network 1 Suppl 3 2003 522 526
112. N. Sykes The relationship between opioid use and laxative use in terminally ill cancer patients Palliat Med 12 1998 375 382
113. I. Mancini, and E. Bruera Constipation in advanced cancer patients Support Care Cancer 6 1998 356 364
114. A.S.D. Kurz Opioid-induced bowel dysfunction Drugs 63 7 2003 649 671
115. N. Sykes Constipation management in palliative care Geriatric Med 27 1997 55 57
116. N. Sykes An investigation of the availability of oral naloxone to correct opioid-related constipation in patients with advanced cancer Palliat Med 10 1996 135 144
117. C.S. Yuan, J.F. Foss, and M. O'Connor Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial JAMA 283 3 2000 367 372
118. W. Schmidt Alvimopan is a novel peripheral antagonist Am J Surg 182 Suppl 5A 2001 27S 38S